Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
July 26, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
All Press Releases for February 22, 2003 Subscribe to this News Feed      
 

The People's Diabetic Fund Honors The Drizen Foundation for Biomedical Research

The People's Diabetic Fund is pleased to announce that the 2003 Diabetic Wound Research Award has been presented to The Drizen Foundation for Biomedical Research because of its involvement with the development of a new topical treatment for diabetic wounds and ulcers [www.drizenfoundation.org, info@drizenfoundation.org, Tel. (905) 893-0631, Fax (905) 893-0689].

NEW YORK & TORONTO---Feb. 18, 2003--The People's Diabetic Fund is pleased to announce that the 2003 Diabetic Wound Research Award has been presented to The Drizen Foundation for Biomedical Research because of its involvement with the development of a new topical treatment for diabetic wounds and ulcers [www.drizenfoundation.org, info@drizenfoundation.org, Tel. (905) 893-0631, Fax (905) 893-0689].

    Accepting on behalf of The Drizen Foundation for Biomedical Research was Alan Drizen, Esq., who has spent over 35 years as a scientist and Senior Executive in the pharmaceutical industry. Alan Drizen holds a significant number of patents in his name as a principal inventor, including 17 Patents issued to him, et al, from the United States Patent Office.

    During the course of his career, Alan Drizen has been responsible for several FDA drug approvals including the Breakthrough Product known as LAM IPM Wound Gel(TM).

    The People's Diabetic Fund is a non-profit, tax-exempt, charitable organization established to raise funds to help eradicate Diabetic Retinopathy and to support The Drizen Foundation for Biomedical Research in its current activities, which are focused on the treatment of certain complications of Diabetes, including wounds, which may result in amputations.

    The current focus of The People's Diabetic Fund is to raise funds to support the development of new diagnostic and treatment modalities for diabetic patients with the vision threatening disease of Diabetic Retinopathy and also to support researchers addressing non-responsive Diabetic Ulcers, which can lead to amputations. There were 86,000 amputations in the United States last year alone, and the numbers are increasing annually.

    You may contact:
    The People's Diabetic Fund
    

  • East 32nd Street
  •     
  • Floor Front
  •     
  • York, NY 10016
  •     Tel. (917) 826-4489 or (212) 689-7373
        
  • (212) 689-5888.
    www.peoplesdiabeticfund.org

OPTIONS
Printer Friendly Version
Email this story to a colleague
CONTACT INFORMATION
Domenic Franco
The Drizen Foundation For Biomedical Research
905-893-0631
Email us Here
ATTACHED FILES

There are no multimedia files attached to this release. If this is your release, you may add images or other multimedia files through your login.

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright